HTLV-1 Infection
5
0
1
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
20.0%
1 terminated out of 5 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma